Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy

<b>Background/Objectives</b>: Near-infrared photoimmunotherapy (NIR-PIT) was recently approved for the treatment of unresectable locally advanced or recurrent head and neck cancers in Japan; however, only one clinical dose has been validated in clinical trials, potentially resulting in e...

Full description

Saved in:
Bibliographic Details
Main Authors: Hideki Tanaka (Author), Yoshikatsu Koga (Author), Mayumi Sugahara (Author), Hirobumi Fuchigami (Author), Akihiro Ishikawa (Author), Toru Yamaguchi (Author), Akiko Banba (Author), Takeshi Shinozaki (Author), Kazuto Matsuura (Author), Ryuichi Hayashi (Author), Shingo Sakashita (Author), Masahiro Yasunaga (Author), Tomonori Yano (Author)
Format: Book
Published: MDPI AG, 2024-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_00d16f467b444f818f61f91e9ddb4734
042 |a dc 
100 1 0 |a Hideki Tanaka  |e author 
700 1 0 |a Yoshikatsu Koga  |e author 
700 1 0 |a Mayumi Sugahara  |e author 
700 1 0 |a Hirobumi Fuchigami  |e author 
700 1 0 |a Akihiro Ishikawa  |e author 
700 1 0 |a Toru Yamaguchi  |e author 
700 1 0 |a Akiko Banba  |e author 
700 1 0 |a Takeshi Shinozaki  |e author 
700 1 0 |a Kazuto Matsuura  |e author 
700 1 0 |a Ryuichi Hayashi  |e author 
700 1 0 |a Shingo Sakashita  |e author 
700 1 0 |a Masahiro Yasunaga  |e author 
700 1 0 |a Tomonori Yano  |e author 
245 0 0 |a Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy 
260 |b MDPI AG,   |c 2024-09-01T00:00:00Z. 
500 |a 10.3390/ph17091246 
500 |a 1424-8247 
520 |a <b>Background/Objectives</b>: Near-infrared photoimmunotherapy (NIR-PIT) was recently approved for the treatment of unresectable locally advanced or recurrent head and neck cancers in Japan; however, only one clinical dose has been validated in clinical trials, potentially resulting in excessive or insufficient dosing. Moreover, IRDye700X (IR700) fluorescence intensity plateaus during treatment, indicating a particular threshold for the antitumor effects. Therefore, we investigated the NIR laser dose across varying tumor sizes and irradiation methods until the antitumor effects of the fluorescence decay rate plateaued. <b>Methods</b>: Mice were subcutaneously transplanted with A431 xenografts and categorized into control, clinical dose (cylindrical irradiation at 100 J/cm², frontal irradiation at 50 J/cm²), and evaluation groups. The rate of tumor IR700 fluorescence intensity decay to reach predefined rates (−0.05%/s or −0.2%/s) until the cessation of light irradiation was calculated using a real-time fluorescence imaging system. <b>Results</b>: The evaluation group exhibited antitumor effects comparable to those of the clinical dose group at a low irradiation dose. Similar results were observed across tumor sizes and irradiation methods. <b>Conclusions</b>: In conclusion, the optimal antitumor effect of NIR-PIT is achieved when the fluorescence decay rate reaches a plateau, indicating the potential to determine the appropriate dose for PIT using a real-time fluorescence monitoring system. 
546 |a EN 
690 |a photoimmunotherapy 
690 |a fluorescence imaging 
690 |a real-time imaging 
690 |a IR700 
690 |a antibody-drug conjugate 
690 |a anticancer therapy 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 17, Iss 9, p 1246 (2024) 
787 0 |n https://www.mdpi.com/1424-8247/17/9/1246 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/00d16f467b444f818f61f91e9ddb4734  |z Connect to this object online.